FLAG induction

PreclinicalSmall molecule

FLAG induction is one of 50 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromesActive, not recruiting

Myelodysplastic SyndromesPreclinical

Active, not recruiting

Competition

Competitive Landscape

207 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Reblozyl

Bristol-Myers Squibb

Phase 3

15 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

8 3

Thalomid

Bristol-Myers Squibb

Phase 3

2 4

Promacta

GSK

Phase 3

2 5

Fludara

Sanofi

Phase 3

2 6

Xospata

Astellas

Phase 3

1 7

Rydapt

Novartis

Phase 3

1 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

4 9

Zarnestra

KKura Oncology, Inc.

Phase 3

4 10

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Withdrawn·UUniversity of Florida·N/A·NCT03446638

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FLAG induction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FLAG induction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FLAG induction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Florida

FLAG induction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News